ipharmacenter Consulting services

Roche recently disclosed promising findings from the phase III lidERA Breast Cancer trial, where their experimental oral drug, giredestrant, showed a significant improvement in invasive disease-free survival compared to standard endocrine therapies. This study involved over 4,100 patients diagnosed with early-stage breast cancer characterized by oestrogen receptor-positive (ER+), HER2-negative tumors. The trial’s interim analysis revealed that giredestrant not only met but su

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab) administered subcutaneously in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least one prior systemic therapy. This newly approved regimen is the first and only bispecific antibody combination therapy available for this patient population. The approval was granted base